Research ExplorerPublicationsThe selective norepinephrine reuptake inhibitor reboxetine p...

The selective norepinephrine reuptake inhibitor reboxetine promotes late-stage fracture healing in mice

Standard

The selective norepinephrine reuptake inhibitor reboxetine promotes late-stage fracture healing in mice. / Donat, Antonia; Jiang, Shan; Xie, Weixin; Knapstein, Paul Richard; Albertsen, Lilly-Charlotte; Kokot, Judith Luisa; Sevecke, Jan; Augustin, Ruben; Jahn, Denise; Yorgan, Timur Alexander; Frosch, Karl-Heinz; Tsitsilonis, Serafeim; Baranowsky, Anke; Keller, Johannes.

In: ISCIENCE, Vol. 26, No. 10, 107761, 20.10.2023.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Donat, A, Jiang, S, Xie, W, Knapstein, PR, Albertsen, L-C, Kokot, JL, Sevecke, J, Augustin, R, Jahn, D, Yorgan, TA, Frosch, K-H, Tsitsilonis, S, Baranowsky, A & Keller, J 2023, 'The selective norepinephrine reuptake inhibitor reboxetine promotes late-stage fracture healing in mice', ISCIENCE, vol. 26, no. 10, 107761. https://doi.org/10.1016/j.isci.2023.107761

APA

Donat, A., Jiang, S., Xie, W., Knapstein, P. R., Albertsen, L-C., Kokot, J. L., Sevecke, J., Augustin, R., Jahn, D., Yorgan, T. A., Frosch, K-H., Tsitsilonis, S., Baranowsky, A., & Keller, J. (2023). The selective norepinephrine reuptake inhibitor reboxetine promotes late-stage fracture healing in mice. ISCIENCE, 26(10), [107761]. https://doi.org/10.1016/j.isci.2023.107761

Vancouver

Donat A, Jiang S, Xie W, Knapstein PR, Albertsen L-C, Kokot JL et al. The selective norepinephrine reuptake inhibitor reboxetine promotes late-stage fracture healing in mice. ISCIENCE. 2023 Oct 20;26(10). 107761. https://doi.org/10.1016/j.isci.2023.107761

Bibtex

@article{4b706fe2e77a4f8389f10421daf0ea6e,
title = "The selective norepinephrine reuptake inhibitor reboxetine promotes late-stage fracture healing in mice",
abstract = "Impaired fracture healing is of high clinical relevance, as up to 15% of patients with long-bone fractures display non-unions. Fracture patients also include individuals treated with selective norepinephrine reuptake inhibitors (SNRI). As SNRI were previously shown to negatively affect bone homeostasis, it remained unclear whether patients with SNRI are at risk of impaired bone healing. Here, we show that daily treatment with the SNRI reboxetine reduces trabecular bone mass in the spine but increases cortical thickness and osteoblast numbers in the femoral midshaft. Most importantly, reboxetine does not impair bone regeneration in a standardized murine fracture model, and even improves callus bridging and biomechanical stability at late healing stages. In sum, reboxetine affects bone remodeling in a site-specific manner. Treatment does not interfere with the early and intermediate stages of bone regeneration and improves healing outcomes of the late-stage fracture callus in mice.",
author = "Antonia Donat and Shan Jiang and Weixin Xie and Knapstein, {Paul Richard} and Lilly-Charlotte Albertsen and Kokot, {Judith Luisa} and Jan Sevecke and Ruben Augustin and Denise Jahn and Yorgan, {Timur Alexander} and Karl-Heinz Frosch and Serafeim Tsitsilonis and Anke Baranowsky and Johannes Keller",
note = "{\textcopyright} 2023 The Author(s).",
year = "2023",
month = oct,
day = "20",
doi = "10.1016/j.isci.2023.107761",
language = "English",
volume = "26",
journal = "ISCIENCE",
issn = "2589-0042",
publisher = "Elsevier Inc.",
number = "10",

}

RIS

TY - JOUR

T1 - The selective norepinephrine reuptake inhibitor reboxetine promotes late-stage fracture healing in mice

AU - Donat, Antonia

AU - Jiang, Shan

AU - Xie, Weixin

AU - Knapstein, Paul Richard

AU - Albertsen, Lilly-Charlotte

AU - Kokot, Judith Luisa

AU - Sevecke, Jan

AU - Augustin, Ruben

AU - Jahn, Denise

AU - Yorgan, Timur Alexander

AU - Frosch, Karl-Heinz

AU - Tsitsilonis, Serafeim

AU - Baranowsky, Anke

AU - Keller, Johannes

N1 - © 2023 The Author(s).

PY - 2023/10/20

Y1 - 2023/10/20

N2 - Impaired fracture healing is of high clinical relevance, as up to 15% of patients with long-bone fractures display non-unions. Fracture patients also include individuals treated with selective norepinephrine reuptake inhibitors (SNRI). As SNRI were previously shown to negatively affect bone homeostasis, it remained unclear whether patients with SNRI are at risk of impaired bone healing. Here, we show that daily treatment with the SNRI reboxetine reduces trabecular bone mass in the spine but increases cortical thickness and osteoblast numbers in the femoral midshaft. Most importantly, reboxetine does not impair bone regeneration in a standardized murine fracture model, and even improves callus bridging and biomechanical stability at late healing stages. In sum, reboxetine affects bone remodeling in a site-specific manner. Treatment does not interfere with the early and intermediate stages of bone regeneration and improves healing outcomes of the late-stage fracture callus in mice.

AB - Impaired fracture healing is of high clinical relevance, as up to 15% of patients with long-bone fractures display non-unions. Fracture patients also include individuals treated with selective norepinephrine reuptake inhibitors (SNRI). As SNRI were previously shown to negatively affect bone homeostasis, it remained unclear whether patients with SNRI are at risk of impaired bone healing. Here, we show that daily treatment with the SNRI reboxetine reduces trabecular bone mass in the spine but increases cortical thickness and osteoblast numbers in the femoral midshaft. Most importantly, reboxetine does not impair bone regeneration in a standardized murine fracture model, and even improves callus bridging and biomechanical stability at late healing stages. In sum, reboxetine affects bone remodeling in a site-specific manner. Treatment does not interfere with the early and intermediate stages of bone regeneration and improves healing outcomes of the late-stage fracture callus in mice.

U2 - 10.1016/j.isci.2023.107761

DO - 10.1016/j.isci.2023.107761

M3 - SCORING: Journal article

C2 - 37720081

VL - 26

JO - ISCIENCE

JF - ISCIENCE

SN - 2589-0042

IS - 10

M1 - 107761

ER -